Celebrating Cha-Mei Tang: A Trailblazer in Cancer Diagnostics Innovation

Cha-Mei Tang: A Leader in Cancer Diagnostics

In a remarkable acknowledgment, Cha-Mei Tang has been honored as a Pinnacle Professional Member of the Inner Circle of Excellence for her significant contributions to cancer diagnostics and screening. Through innovative technologies, particularly the LifeTracDx® blood test, Dr. Tang is paving the way for a new era in cancer care.

For over 15 years, Dr. Tang has been dedicated to transforming the cancer treatment landscape. Her journey began with the establishment of Creatv MicroTech in 2010, focusing on microfabrication technologies designed to capture circulating tumor cells (CTCs) in the blood of cancer patients. This approach led to the discovery of cancer-associated macrophage-like cells (CAMLs), which are now recognized as pivotal biomarkers in cancer diagnostics.

The LifeTracDx® Breakthrough

One of the flagship innovations from Dr. Tang’s research is the LifeTracDx® blood test. This test is unique in its ability to provide real-time insights across various cancer types without the need for invasive tissue samples. Its wide-ranging capabilities include:

1. Real-Time Prognosis: Offering immediate insights at any given moment.
2. Predictive Outcomes: Estimating treatment response within approximately 30 days of the first therapy dose.
3. Companion Diagnostics: Providing critical correlations on treatment efficacy without requiring surgical biopsies.
4. Monitoring Biomarkers: Observing changes in tumor markers, such as PD-L1, which are essential for immunotherapy decision-making.
5. Detecting Recurrence: Identifying cancer recurrence and assessing minimal residual disease (MRD).
6. High-Quality Tumor DNA: Isolating DNA for sequencing to study tumor genetics.

The clinical validity and reliability of LifeTracDx® signify a groundbreaking development in the realm of oncology. These details enable oncologists to make informed decisions that could substantially improve patient outcomes and possibly save lives.

Dr. Tang's Academic and Professional Journey

Dr. Tang's academic credentials are extensive, having earned multiple degrees from the Massachusetts Institute of Technology (MIT), including a Doctor of Science in Electrical Engineering and Computer Science. Her professional experiences span notable institutions, including a leadership role at the U.S. Naval Research Laboratory and research at the National Institute of Standards and Technology (NIST).

Over the years, Dr. Tang's contributions have not gone unnoticed; she earned the prestigious WISE Award for Science in 1992 and was named a Senior Member of IEEE, among other accolades. Her induction into Marquis Who's Who in 2024 further underscores her status as a leader in her field.

Future Directions in Cancer Diagnostics

Currently, Dr. Tang is directing her efforts toward obtaining FDA approval for various applications of the LifeTracDx® test. The recent CLIA certification of Creatv MicroTech's lab in Monmouth Junction, NJ, allows it to perform the LifeTracDx® tests, broadening therapeutic partnerships with cancer drug companies to understand their treatments better.

Dr. Tang remains actively involved in various professional organizations, including the American Association for Cancer Research (AACR) and the American Society of Clinical Oncology (ASCO). Her team frequently presents their cutting-edge research at renowned conferences, bolstering the field of cancer diagnostics.

Conclusion

Cha-Mei Tang's relentless pursuit of innovation in cancer diagnostics represents a beacon of hope for early detection and effective treatment. As she continues her work, the future of cancer care may soon see substantial improvements, leading to better survival rates and quality of life for countless individuals affected by this disease.

With technologies evolving under her guidance, a future where cancer is detected at its nascent stage appears more attainable, emphasizing her commitment to advancing healthcare and saving lives.